Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodie...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical cancer research Ročník 26; číslo 5; s. 984
Hlavní autoři:	Autio, Karen A, Boni, Valentina, Humphrey, Rachel W, Naing, Aung
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.03.2020
Témata:	Animals Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Immunotherapy - adverse effects Neoplasms - drug therapy Neoplasms - immunology Prodrugs - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors
ISSN:	1557-3265, 1557-3265
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies.
AbstractList	The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies.The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies. The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies.
Author	Autio, Karen A Humphrey, Rachel W Boni, Valentina Naing, Aung
Author_xml	– sequence: 1 givenname: Karen A surname: Autio fullname: Autio, Karen A email: autiok@mskcc.org organization: Genitourinary Oncology Service/Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. autiok@mskcc.org – sequence: 2 givenname: Valentina orcidid: 0000-0002-8675-0018 surname: Boni fullname: Boni, Valentina organization: START Madrid-CIOCC HM University Hospital Sanchinarro, Madrid, Spain – sequence: 3 givenname: Rachel W surname: Humphrey fullname: Humphrey, Rachel W organization: CytomX Therapeutics, Inc., South San Francisco, California – sequence: 4 givenname: Aung orcidid: 0000-0002-4803-8513 surname: Naing fullname: Naing, Aung organization: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31601568$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE1LxDAQhoMofv8EJUcv0UzapNGb1PUDhBWp5yWbTrqRNlmbFt0f4v-14AqeZuZ9H-bwHJHdEAMScgb8EkDqK-CFZjzPxGVZvjK4ZpDLYoccgpQFy4SSu__2A3KU0jvnkAPP98lBBoqDVPqQfL_0cRnrDa1W2Js1joO36YbeBjrrsG98aGjZmpRodFvEY6J3mHwTsKZDpLOwMsEinQdWmb7Bgc6cQzsk-umHFX3FerQTOXeOVWMXe1rFL2_9sKFuOt4SUh_oU9eNIbJ5sLGNzeaE7DnTJjzdzmPydj-rykf2PH94Km-fmc0BBlYvl3VRgKxVobWWNYgcMmX1tZx6FFIoY_SU6YIrYY1CVCi5cloiotBOHJOL37_rPn6MmIZF55PFtjUB45gWIuOST85AT-j5Fh2XHdaLde87028WfyrFDwrXeRo
CitedBy_id	crossref_primary_10_3390_cancers14225674 crossref_primary_10_1038_s41585_025_01014_w crossref_primary_10_3390_antib9040065 crossref_primary_10_1200_EDBK_281107 crossref_primary_10_1016_j_immuni_2023_06_003 crossref_primary_10_14336_AD_2024_0546 crossref_primary_10_1016_j_apsb_2024_03_027 crossref_primary_10_1007_s11684_024_1072_8 crossref_primary_10_1038_s41571_023_00783_w crossref_primary_10_1208_s12248_021_00594_w crossref_primary_10_3389_fimmu_2025_1609871 crossref_primary_10_1158_0008_5472_CAN_21_2483 crossref_primary_10_1038_s43018_023_00536_9 crossref_primary_10_3390_pharmaceutics13091390 crossref_primary_10_1016_j_jconrel_2021_10_006 crossref_primary_10_1111_jcmm_18101 crossref_primary_10_3390_antib14010007 crossref_primary_10_1136_jitc_2021_002949 crossref_primary_10_1007_s11864_023_01072_5 crossref_primary_10_1007_s10549_021_06423_0 crossref_primary_10_1038_s41570_020_00241_6 crossref_primary_10_3390_cancers15061794 crossref_primary_10_1073_pnas_2025930118 crossref_primary_10_3390_cancers15030713 crossref_primary_10_1038_s41577_023_00982_7 crossref_primary_10_1016_j_annonc_2020_11_018 crossref_primary_10_3390_cancers12010038 crossref_primary_10_1186_s40001_024_01901_9 crossref_primary_10_1016_j_jpba_2023_115580 crossref_primary_10_1038_s41571_020_0403_1 crossref_primary_10_1016_j_biopha_2025_118593 crossref_primary_10_1016_j_drup_2024_101086 crossref_primary_10_1016_j_heliyon_2024_e37263 crossref_primary_10_12677_PI_2021_103017 crossref_primary_10_2174_0118715206348204241128063329 crossref_primary_10_1080_14728222_2025_2563244 crossref_primary_10_1016_j_tips_2024_10_005 crossref_primary_10_1007_s11899_021_00628_2 crossref_primary_10_1007_s12032_025_02610_x crossref_primary_10_1021_acscentsci_2c00576 crossref_primary_10_1158_2326_6066_CIR_21_0031 crossref_primary_10_3389_fimmu_2023_1295599 crossref_primary_10_1093_jjco_hyae054 crossref_primary_10_1038_s41571_021_00507_y crossref_primary_10_1016_j_jconrel_2023_03_046 crossref_primary_10_1158_0008_5472_CAN_20_1117 crossref_primary_10_1007_s11912_024_01576_9 crossref_primary_10_1016_j_phrs_2021_105997 crossref_primary_10_1126_science_abg1209 crossref_primary_10_3389_fimmu_2021_780399 crossref_primary_10_3389_fimmu_2023_1203073 crossref_primary_10_1158_1078_0432_CCR_21_2182 crossref_primary_10_1021_jacs_4c04894 crossref_primary_10_3389_fimmu_2022_982902 crossref_primary_10_1038_s41568_024_00690_x crossref_primary_10_1080_17425247_2025_2531064 crossref_primary_10_3390_cells12040631 crossref_primary_10_3390_cancers14030778 crossref_primary_10_1038_s41573_024_00896_6 crossref_primary_10_3389_fonc_2024_1459368 crossref_primary_10_1016_j_lfs_2024_122676 crossref_primary_10_3390_ph18020180 crossref_primary_10_1016_j_nbt_2022_12_002 crossref_primary_10_1002_cac2_12517 crossref_primary_10_3390_cancers12082223 crossref_primary_10_1016_j_yrtph_2020_104813 crossref_primary_10_1136_jitc_2022_004757 crossref_primary_10_1016_j_xcrm_2025_102191 crossref_primary_10_1038_s41557_023_01280_4 crossref_primary_10_3390_antib12030055 crossref_primary_10_1080_00498254_2024_2381139 crossref_primary_10_3389_fimmu_2022_1035276 crossref_primary_10_3389_fimmu_2024_1447021 crossref_primary_10_3390_cancers15082352 crossref_primary_10_1007_s11864_022_01018_3 crossref_primary_10_1002_cpt_1961 crossref_primary_10_1097_CCO_0000000000000869 crossref_primary_10_1136_jitc_2021_002447 crossref_primary_10_1016_j_crmeth_2025_101077 crossref_primary_10_1021_jacs_4c04035 crossref_primary_10_1136_jitc_2021_002446 crossref_primary_10_3390_pharmaceutics17091164 crossref_primary_10_1002_advs_202206912 crossref_primary_10_1016_j_drudis_2024_104057 crossref_primary_10_1126_sciimmunol_abi6899 crossref_primary_10_1007_s10549_021_06405_2 crossref_primary_10_3390_biology13050307 crossref_primary_10_1016_j_immuni_2020_04_011 crossref_primary_10_3892_or_2024_8854 crossref_primary_10_1016_j_critrevonc_2025_104905 crossref_primary_10_1007_s40259_022_00518_w crossref_primary_10_3390_ijms21228678 crossref_primary_10_1016_j_copbio_2022_102809 crossref_primary_10_3389_fimmu_2020_01508 crossref_primary_10_1080_19420862_2024_2373325 crossref_primary_10_3389_fimmu_2022_757480 crossref_primary_10_1016_j_addr_2021_113969 crossref_primary_10_1038_s41551_022_00888_0 crossref_primary_10_1093_abt_tbac014 crossref_primary_10_1038_s41573_021_00259_5 crossref_primary_10_3390_ph15050508 crossref_primary_10_1016_j_xphs_2020_09_025 crossref_primary_10_1126_sciimmunol_abf4034
ContentType	Journal Article
Copyright	2019 American Association for Cancer Research.
Copyright_xml	– notice: 2019 American Association for Cancer Research.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/1078-0432.CCR-19-1457
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1557-3265
ExternalDocumentID	31601568
Genre	Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P30 CA008748
GroupedDBID	--- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8 AAFWJ AAJMC
ID	FETCH-LOGICAL-c411t-dbbd7715d678885d124136c895c41e2526aa824187062ca6ee6e506f85eee28f2
IEDL.DBID	7X8
ISICitedReferencesCount	135
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000518188000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1557-3265
IngestDate	Fri Sep 05 09:11:17 EDT 2025 Wed Feb 19 02:29:48 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
License	2019 American Association for Cancer Research.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c411t-dbbd7715d678885d124136c895c41e2526aa824187062ca6ee6e506f85eee28f2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ORCID	0000-0002-4803-8513 0000-0002-8675-0018
OpenAccessLink	https://aacrjournals.org/clincancerres/article-pdf/26/5/984/2065734/984.pdf
PMID	31601568
PQID	2305041018
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2305041018 pubmed_primary_31601568
PublicationCentury	2000
PublicationDate	2020-03-01
PublicationDateYYYYMMDD	2020-03-01
PublicationDate_xml	– month: 03 year: 2020 text: 2020-03-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical cancer research
PublicationTitleAlternate	Clin Cancer Res
PublicationYear	2020
SSID	ssj0014104
Score	2.6288514
SecondaryResourceType	review_article
Snippet	The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	984
SubjectTerms	Animals Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Immunotherapy - adverse effects Neoplasms - drug therapy Neoplasms - immunology Prodrugs - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors
Title	Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
URI	https://www.ncbi.nlm.nih.gov/pubmed/31601568 https://www.proquest.com/docview/2305041018
Volume	26
WOSCitedRecordID	wos000518188000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaAIsSFN7S8NEhcDWtvbGe5oGppBRLdXVWptLdV4ozVHrDbzRaxP4T_y4yTak9ISFxySCZK5HyezMw3DyHeY-Ea0o0osSAVWOC4pj3XeEniQROoQ9sXCn93s1m5XE4WQ8CtG9Iqb3RiVtRt8hwj_0imshkV3F_q8-WV5KlRzK4OIzRui70xmTKMarfcsQgknlllY2gjaWuGCh5lSlIW3Fm2GOsP0-mpVBOpCuP-bmXmv83xw_99z0fiwWBnwmEPjMfiFsYn4t7JwKQ_Fb8X69SkdgvVrgCr-wSHEThMxZOLIM_LhBQGEXKp4UvO98AWNgmO4jkjBuZRVjmdHPpOyB1wbBdOuScsSc5DkNX1j7SGKv2ih2-2QHYynHUIFxG-cXlKkvOYm2dvn4mz46Nq-lUOIxqkL5TayLZpWueUaS270qZVTNNZX04MXUdttK3rks4xm6p9bREtmpENpUFEXQb9XNyJKeK-AO3J1xt5h6VtC6vqiTINIcU6h-iVDQfi3c2Cr2gLMK9RR0zX3Wq35AfiRf_VVpd9r47VWFkuFi9f_sPdr8R9zd50zjB7LfYCKQB8I-76n5uLbv02Y4uOs8XJH2FB2JQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Probody+Therapeutics%3A+An+Emerging+Class+of+Therapies+Designed+to+Enhance+On-Target+Effects+with+Reduced+Off-Tumor+Toxicity+for+Use+in+Immuno-Oncology&rft.jtitle=Clinical+cancer+research&rft.au=Autio%2C+Karen+A&rft.au=Boni%2C+Valentina&rft.au=Humphrey%2C+Rachel+W&rft.au=Naing%2C+Aung&rft.date=2020-03-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=26&rft.issue=5&rft.spage=984&rft_id=info:doi/10.1158%2F1078-0432.CCR-19-1457&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3265&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3265&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3265&client=summon